HRT for Women: The 2026 Physician Guide

What it treats

What HRT Actually Treats

Estrogen loss at menopause produces a recognizable pattern of symptoms: vasomotor symptoms (hot flashes and night sweats), sleep disruption, mood instability, brain-fog cognitive symptoms, genitourinary syndrome of menopause (vaginal dryness, recurrent UTIs, painful sex), and accelerated bone loss. HRT directly addresses each of these by restoring physiologic hormone levels.

Many women are told these symptoms are “normal aging” and offered antidepressants, sleep medications, or vaginal moisturizers individually. HRT, when appropriate, treats the cause rather than the downstream symptoms one at a time.

Types

Types of HRT: Estrogen, Progesterone, Testosterone, Routes

• ·Estrogen. The active treatment for vasomotor and genitourinary symptoms and for bone protection. Available as patches, gels, sprays, rings, vaginal preparations, and oral tablets.
• ·Progesterone. Required for women with an intact uterus to protect the endometrium from unopposed estrogen. Micronized progesterone (Prometrium and equivalents) is the most physiologic form.
• ·Testosterone. Off-label in the U.S. for women but used clinically by experienced menopause physicians for low libido, energy, and muscle/bone support. Dosing is a fraction of male dosing.
• ·Transdermal vs. oral. Transdermal estrogen is preferred for women with cardiovascular risk factors, migraine, or VTE history because it bypasses first-pass liver metabolism and does not raise clotting factor production the way oral estrogen does.

History

The WHI Controversy and What We Now Understand

The 2002 Women's Health Initiative early-termination announcement caused HRT prescribing to collapse for two decades. The original headline — that HRT increased breast cancer and cardiovascular events — was substantially miscommunicated.

Reanalysis of the WHI data showed the effects were driven largely by an older cohort (average age 63 at enrollment, many more than a decade past menopause) and by the specific combination used (conjugated equine estrogens plus medroxyprogesterone acetate). For women within 10 years of menopause and under age 60, the cardiovascular risk signal disappears and the breast-cancer signal is smaller than commonly reported.

The Menopause Society's current position is that the benefits of HRT outweigh the risks for most symptomatic women under 60 or within 10 years of menopause, when therapy is individualized.

Candidacy

Who Is a Candidate

Generally appropriate candidates: women under 60 or within 10 years of menopause with bothersome vasomotor symptoms, genitourinary syndrome, or accelerated bone loss; women with premature ovarian insufficiency (regardless of age); women with significant quality-of-life impact from menopausal symptoms.

Caution or contraindication: history of estrogen-receptor-positive breast cancer, untreated endometrial cancer, active liver disease, history of VTE or stroke (transdermal preferred if used), undiagnosed vaginal bleeding, known thrombophilia.

Candidacy is not a checkbox. It is a conversation between a patient and a physician who treats menopause routinely.

Risks & benefits

Risks and Benefits — The Honest, Current Picture

Documented benefits: reliable relief of vasomotor and genitourinary symptoms; preservation of bone density and reduction in osteoporotic fracture; likely cardiovascular protection when initiated in the early postmenopausal window; quality-of-life improvements in sleep, mood, and sexual function.

Documented risks: small absolute increase in breast cancer with combined estrogen-progesterone after several years of use; small VTE risk with oral estrogen, minimal with transdermal; small stroke risk with oral estrogen in older women.

Absolute risk for an individual patient under 60 starting within 10 years of menopause is small enough that for most symptomatic women the benefits clearly outweigh the risks.

Bioidentical

Bioidentical vs. Conventional HRT

“Bioidentical” means hormones structurally identical to those the body produces — estradiol, estriol, micronized progesterone. Many FDA-approved HRT products are bioidentical (transdermal estradiol, oral micronized progesterone).

“Compounded bioidentical hormone therapy” (cBHT) — custom-formulated by compounding pharmacies, often with saliva-test-based dosing — is a separate category. The major medical societies (Menopause Society, ACOG, Endocrine Society) recommend FDA-approved bioidentical products over compounded ones because compounded products lack the dose-consistency and safety data of approved formulations.

How to start

Working With a Physician

Productive workups include a full symptom and medical history, blood pressure, breast and pelvic exam where indicated, baseline labs (lipid panel, HbA1c, TSH, vitamin D; FSH/estradiol where helpful, though menopause is a clinical diagnosis), and mammogram per screening guidelines.

Treatment is individualized: route (transdermal first for most), dose (lowest effective), and combination (cyclic vs. continuous progesterone). Reassessment at 3 months, then annually, is standard.

The right physician to manage HRT is one who treats menopause routinely — many gynecologists, some internists, and physicians with Menopause Society certification.